glp-1 drugs cancer Do GLP-1s Lower Risk? Glucagon-like peptide 1 receptor agonist

10.1016/j.ajo.2024.08.030

GLP-1 RAs may provide additional therapeutic benefits beyond glycemic control due to their multifaceted metabolic and anti-inflammatory properties

Watch reporters Jeanne Lenzer and Shannon Brownlee explain what they found: how the FDA approved 73 % of new drugs without solid proof they work and how drug-company money now funds two-thirds of the agencys budget

The assessment of binge eating severity among obese persons

Localized reactions have been reported in patients using liraglutide and dulaglutide [43,44,45,46], while generalized urticaria and systemic anaphylaxis have been associated with exenatide and tirzepatide [47,48,49,50,51]

Given the relatively high monthly cost of GLP-1s in the US, as well as the prevalence of obesity in that market, GLP-1s have attracted particular attention